Structure-Based Drug Design of Novel Indazole/Indolinone-Based Biaryl Derivatives as Oral IRAK4 Inhibitors for the Treatment of Inflammatory Diseases.
Compound 43 exhibited potent molecular and cellular IRAK4 inhibitory activities as well as in vivo anti-inflammatory activities in both LPS-induced acute inflammation and collagen-induced arthritis models alongside favorable pharmacokinetic properties, indicating that compound 43 is a valuable lead compound for further...